Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor

A compound of formula (I) or a pharmaceutically acceptable salt thereof,

• wherein
• ring A is selected from 3-8 membered heterocycloalkyl, and the 3-8 membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R;
• R1, R2, R3, R4 and R5 are each independently selected from H, halogen, OH, NH2, CN, C1-6 alkyl and C1-6 heteroalkyl, and the C1-6 alkyl and C1-6 heteroalkyl are optionally substituted with 1, 2 or 3 R;
• or R1 and R2 are connected together to form ring B;
• or R2 and R3 are connected together to form ring B;
• or R3 and R4 are connected together to form ring B;
• or R4 and R5 are connected together to form ring B;
• ring B is selected from phenyl, C5-6 cycloalkenyl, 5-6 membered heterocycloalkenyl and 5-6 membered heteroaryl, and the phenyl, C5-6 cycloalkenyl, 5-6 membered heterocycloalkenyl and 5-6 membered heteroaryl are optionally substituted with 1, 2 or 3 Ra;
• Ra is selected from halogen, OH, NH2, CN, C1-6 alkyl and C1-6 heteroalkyl, and the C1-6 alkyl and C1-6 heteroalkyl are optionally substituted with 1, 2 or 3 R;
• R6 is selected from H, halogen and C1-6 alkyl, and the C1-6 alkyl is optionally substituted with 1, 2 or 3 R;
• R7 is selected from 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and C5-6 cycloalkyl, and 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and C5-6 cycloalkyl are optionally substituted with 1, 2 or 3 R;
• L is selected from a single bond, —NH—, —S—, —O—, —C(═O)—, —C(═S)—, —CH2—, —CH(Rb)— and —C(Rb)2—;
• L′ is selected from a single bond and —NH—;
• Rb is selected from C1-3 alkyl and C1-3 heteroalkyl, and the C1-3 alkyl and C1-3 heteroalkyl are optionally substituted with 1, 2 or 3 R;
• R8 is selected from H, C1-6 alkyl and C1-6 heteroalkyl, and the C1-6 alkyl and C1-6 heteroalkyl are optionally substituted with 1, 2 or 3 R;
• R is selected from halogen, OH, NH2, CN, C1-6 alkyl, C1-6 heteroalkyl and C3-6 membered cycloalkyl, and the C1-6 alkyl, C1-6 heteroalkyl and C3-6 membered cycloalkyl are optionally substituted with 1, 2 or 3 R′;
• R′ is selected from F, Cl, Br, I, OH, NH2, CN, CH3, CH3CH2, CH3O, CF3, CHF2, CH2F, cyclopropyl, propyl, isopropyl, N(CH3)2 and NH(CH3);
• “hetero” means a heteroatom or a heteroatomic group, the “hetero” in the 3-8 membered heterocycloalkyl, C1-6 heteroalkyl, 5-6 membered heterocycloalkenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl and C1-3 heteroalkyl is each independently selected from —C(═O)N(R)—, —N(R)—, —NH—, N, —O—, —S—, —C(═O)O—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2— and —N(R)C(═O)N(R)—;
• in any of the cases above, the number of heteroatoms or heteroatomic groups is each independently selected from 1, 2 and 3.